Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 336

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 336
---
MENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated OtherComprehensive LossAccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar ValueBalance at December 31, 202431,050,448$31,050 —$— $265,650,362 $— $(224,295,186)$41,386,226 Issuance of common stock under at-the-market offering, net of issuance costs4,836,8044,837 —— 13,671,830 — — 13,676,667 Issuance of common stock through employee stock purchase plan98,45098 —— 133,794 — — 133,892 Stock-based compensation expense—— —— 1,692,267 — — 1,692,267 Net loss—— —— — — (15,046,132)(15,046,132)Balance at March 31, 202535,985,702$35,985 —$— $281,148,253 $— $(239,341,318)$41,842,920 Issuance of common stock upon exercise of stock options1,6042 —— 2,053 — — 2,055 Stock-based compensation expense—— —— 1,524,943 — — 1,524,943 Net loss—— —— — — (14,433,881)(14,433,881)Balance at June 30, 202535,987,306$35,987 —$— $282,675,249 $— $(253,775,199)$28,936,037 Issuance of common stock upon exercise of stock options47,22147 —— 136,598 — — 136,645 Issuance of common stock through employee stock purchase plan201,693202 —— 287,816 — — 288,018 Issuance of common stock under at-the-market offering, net of issuance costs327,355327 —— 1,343,052 — — 1,343,379 Issuance of common stock, pre-funded warrants, and common stock warrants through private placement, net of $1.6 million in placement costs5,